Corvus Pharmaceuticals マネジメント
マネジメント 基準チェック /24
Corvus Pharmaceuticalsの CEO はRick Millerで、 Feb2014年に任命され、 の在任期間は 12.25年です。 の年間総報酬は$ 7.03Mで、 0.5%給与と99.5%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の2.76%を直接所有しており、その価値は$ 29.83M 。経営陣と取締役会の平均在任期間はそれぞれ9年と7.3年です。
主要情報
Rick Miller
最高経営責任者
US$7.0m
報酬総額
| CEO給与比率 | 0.52% |
| CEO在任期間 | 12.3yrs |
| CEOの所有権 | 2.8% |
| 経営陣の平均在職期間 | 9yrs |
| 取締役会の平均在任期間 | 7.3yrs |
経営陣の近況
Recent updates
Seeking Alpha • Apr 08
Corvus Pharmaceuticals: Strong Clinical Narrative, Already Priced For Success
Summary Corvus Pharmaceuticals is built on ITK inhibition, showing early promising data in both PTCL and atopic dermatitis. CRVS’s soquelitinib demonstrates superior mPFS and OS in PTCL versus historical controls, but data is early and from small cohorts. The current $1.24B valuation fully prices in success for both PTCL and AD, despite only early-stage clinical validation. I rate CRVS a sell at current prices due to market enthusiasm outpacing clinical and commercial proof. Read the full article on Seeking Alpha
新しいナラティブ • Apr 02
Multiple Trial And Dilution Risks Will Shape Future Immunology Upside Potential
Catalysts About Corvus Pharmaceuticals Corvus Pharmaceuticals focuses on developing soquelitinib, a selective ITK inhibitor, for immune mediated diseases and cancers. What are the underlying business or industry changes driving this perspective?
新しいナラティブ • Mar 19
Late Stage ITK Inhibitor Franchise Will Transform Immunology Pipeline Over The Long Term
Catalysts About Corvus Pharmaceuticals Corvus Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing soquelitinib, a selective ITK inhibitor, for cancers and immune inflammatory diseases. What are the underlying business or industry changes driving this perspective?
新しいナラティブ • Mar 05
Targeted Immunology Pipeline Will Position This Biotech For Multiple Long Term Catalysts
Catalysts About Corvus Pharmaceuticals Corvus Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing soquelitinib, an oral ITK inhibitor, for immune and inflammatory diseases and T cell lymphomas. What are the underlying business or industry changes driving this perspective?分析記事 • Nov 01
We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...分析記事 • Aug 19
Is Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Trading At A 49% Discount?
Key Insights Corvus Pharmaceuticals' estimated fair value is US$10.34 based on 2 Stage Free Cash Flow to Equity Current...分析記事 • Jul 15
Corvus Pharmaceuticals (NASDAQ:CRVS) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. Indeed, Corvus...Seeking Alpha • Mar 28
Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials
Summary Corvus Pharmaceuticals' leading drug candidate is Soquelitinib, which has broad potential across PTCL, atopic dermatitis, and ALPS. Unfortunately, it seems Corvus' early AD data might have disappointed investors (at least initially). Still, Soquelitinib's promising Phase 3 PTCL trial results are due late 2026. Its PFS metrics might help it to differentiate from other standard chemotherapy treatments. As for Soquelitinib’s early AD results, I believe they were mostly positive, but they were based on limited data of just 28 days and 19 patients. Unfortunately, while Corvus' pipeline progress has been solid, they’re now running into dilution risks due to their short cash runway. Hence, I believe CRVS stock is a “Hold” now. Read the full article on Seeking AlphaSeeking Alpha • Mar 03
Corvus Pharmaceuticals: Small Market, Many Competitors, Low Cash Balance
Summary Corvus Pharmaceuticals' lead asset, Soquelitinib, shows promising early data in treating peripheral T cell lymphoma, solid tumors, and atopic dermatitis. Despite competitive clinical data, Corvus faces significant financial risks with limited cash reserves and a small, highly differentiated PTCL market. The company has a market cap of $259 million and a cash runway of approximately six quarters, raising concerns about funding future trials and commercialization. Given the financial constraints and competitive landscape, I recommend staying on the sidelines for now. Read the full article on Seeking Alpha分析記事 • Jan 13
We're Not Worried About Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Corvus...Seeking Alpha • Dec 18
Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting
Summary Positive results released from phase 1 study, using 100 mg twice daily oral dosing soquelitinib for the treatment of patients with Atopic Dermatitis; Several other cohorts testing higher dosing. The global atopic dermatitis market size is projected to reach $22.6 billion by 2031. Corvus is developing next-generation ITK inhibitors which are going to offer a more tailored approach to targeting specific immunological disorders. The company received a $12.7 million cash infusion from warrant exercises, bolstering its financial position and future development. Read the full article on Seeking AlphaSeeking Alpha • Nov 13
Corvus Pharmaceuticals: The Market Likes The Story
Summary Today, we take a look at Corvus Pharmaceuticals, whose stock has rocketed from under $2 a share this summer to around ten bucks a share. The company is advancing a couple of intriguing candidates within its developmental pipeline and recently kicked off a pivotal Phase 3 registrational study. Can the rally continue as the market increasingly buys into the story around Corvus, or is some profit taking on the horizon? An analysis around Corvus Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Sep 02
Corvus Pharmaceuticals: Soquelitinib's High Stakes In PTCL Therapy
Summary Corvus Pharmaceuticals is advancing soquelitinib, an ITK inhibitor, for peripheral T-cell lymphoma with a Phase 3 trial expected to start soon. Soquelitinib has shown promising Phase 1 data, particularly in patients with fewer prior therapies, but results in heavily pretreated patients are less encouraging. The drug's novel mechanism targets T-cell signaling to promote antitumor immunity, differentiating it from other treatments in PTCL. While soquelitinib's potential in PTCL is notable, the stock is best rated as a "hold" due to high uncertainty and the need for more conclusive clinical data. Read the full article on Seeking Alpha分析記事 • Mar 06
Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. Indeed, Corvus...分析記事 • Oct 23
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...分析記事 • May 16
Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • Dec 05
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Sep 26
Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China
Clinical-stage biopharma Corvus Pharmaceuticals (NASDAQ:CRVS) on Monday said an investigational new drug application to start a phase 1/1b trial of monoclonal antibody mupadolimab had been approved by China's drug regulator. The study was approved by the Center for Drug Evaluation of the China National Medical Products Administration, and will be conducted by Angel Pharmaceuticals, CRVS' partner in the Asian country. Mupadolimab is being evaluated for the treatment of patients with relapsed refractory non-small cell lung cancer and head and neck squamous cell cancers. Angel Pharma, a privately-held biopharma, was co-founded by CRVS to develop its pipeline in greater China. Angel Pharma licensed the rights from CRVS to develop, make and commercialize mupadolimab in greater China, Corvus (CRVS) said in a statement. CRVS stock +5% to $0.76 after hours.分析記事 • Aug 14
We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...分析記事 • Apr 05
Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...分析記事 • Dec 15
We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Dec 10
Checking In On Corvus Pharmaceuticals
Today, we look at Corvus Pharmaceuticals, a company that has multiple candidates in development. The stock has had a roller coaster ride so far in 2021. A full investment analysis is presented in the paragraphs below.Seeking Alpha • Sep 22
Corvus: Surging On AstraZeneca CD73 Success With Key Data Readout Looming
Corvus stock has made spectacular gains across the past week, rising from a price of $2.3 to $8.5 - a 270% gain. Last week, AstraZeneca's Oleclumab - an anti-CD73 therapy - substantially improved the risk of death in combo with IMFINZI in NSCLC. Corvus' Mupadolimab is an anti-CD73 monoclonal antibody and hopes are high that it can show similar efficacy to Oleclumab. Corvus recently discontinued the development of Mupadolimab as a COVID therapy and resumed trials of the drug in head and neck cancer. Data from that trial, and an expansion cohort in combo with Merck's Keytruda, ought to read out this year - a potentially exciting catalyst. Corvus deserves its recent uplift, in my view, but still has much to prove.分析記事 • Aug 26
We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • May 08
Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...分析記事 • Feb 19
The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares
Investors who take an interest in Corvus Pharmaceuticals, Inc. ( NASDAQ:CRVS ) should definitely note that the...分析記事 • Feb 07
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...分析記事 • Dec 16
Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like
Every investor in Corvus Pharmaceuticals, Inc. ( NASDAQ:CRVS ) should be aware of the most powerful shareholder groups...CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$44m |
| Dec 31 2025 | US$7m | US$37k | -US$15m |
| Sep 30 2025 | n/a | n/a | -US$15m |
| Jun 30 2025 | n/a | n/a | -US$45m |
| Mar 31 2025 | n/a | n/a | -US$41m |
| Dec 31 2024 | US$3m | US$33k | -US$62m |
| Sep 30 2024 | n/a | n/a | -US$57m |
| Jun 30 2024 | n/a | n/a | -US$23m |
| Mar 31 2024 | n/a | n/a | -US$25m |
| Dec 31 2023 | US$1m | US$110k | -US$27m |
| Sep 30 2023 | n/a | n/a | -US$30m |
| Jun 30 2023 | n/a | n/a | -US$39m |
| Mar 31 2023 | n/a | n/a | -US$41m |
| Dec 31 2022 | US$524k | US$300k | -US$41m |
| Sep 30 2022 | n/a | n/a | -US$41m |
| Jun 30 2022 | n/a | n/a | -US$37m |
| Mar 31 2022 | n/a | n/a | -US$40m |
| Dec 31 2021 | US$905k | US$300k | -US$43m |
| Sep 30 2021 | n/a | n/a | -US$7m |
| Jun 30 2021 | n/a | n/a | -US$6m |
| Mar 31 2021 | n/a | n/a | -US$5m |
| Dec 31 2020 | US$1m | US$300k | -US$6m |
| Sep 30 2020 | n/a | n/a | -US$44m |
| Jun 30 2020 | n/a | n/a | -US$46m |
| Mar 31 2020 | n/a | n/a | -US$48m |
| Dec 31 2019 | US$1m | US$300k | -US$47m |
報酬と市場: Rickの 総報酬 ($USD 7.03M ) は、 US市場 ($USD 3.70M ) の同規模の企業の平均を上回っています。
報酬と収益: Rickの報酬は増加しましたが、会社は利益を上げていません。
CEO
Rick Miller (74 yo)
12.3yrs
在職期間
US$7,031,566
報酬
Dr. Richard A. Miller, also known as Rick, M.D., serves as Director of BrainScope Company Inc. since September 2023. He is a Co-Founder of Corvus Pharmaceuticals, Inc. and has been its Chief Executive Offi...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder | 12.3yrs | US$7.03m | 2.76% $ 29.8m | |
| Co-Founder & Independent Director | no data | US$97.47k | 0% $ 0 | |
| Chief Financial Officer | 11.5yrs | US$3.21m | 0.34% $ 3.6m | |
| Senior Vice President of Pharmaceutical Development | 6.4yrs | US$3.16m | 0.21% $ 2.2m | |
| Senior VP & Chief Business Officer | 2.3yrs | データなし | データなし |
9.0yrs
平均在職期間
65yo
平均年齢
経験豊富な経営陣: CRVSの経営陣は経験豊富で経験豊富です（平均在職期間は9年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder | 12.3yrs | US$7.03m | 2.76% $ 29.8m | |
| Co-Founder & Independent Director | 11.5yrs | US$97.47k | 0% $ 0 | |
| Independent Director | 1.1yrs | US$105.65k | 0.19% $ 2.1m | |
| Independent Director | 7.3yrs | US$99.47k | 0.012% $ 128.3k | |
| Independent Director | 9.3yrs | US$95.47k | 0% $ 0 | |
| Independent Director | less than a year | データなし | データなし | |
| Independent Director | less than a year | US$182.24k | データなし |
7.3yrs
平均在職期間
65yo
平均年齢
経験豊富なボード: CRVSの 取締役会 は 経験豊富 であると考えられます ( 7.3年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/27 21:54 |
| 終値 | 2026/05/27 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Corvus Pharmaceuticals, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。13
| アナリスト | 機関 |
|---|---|
| Etzer Darout | Barclays |
| Dane Leone | BTIG |
| Li Wang Watsek | Cantor Fitzgerald & Co. |